Selective Antibodies for Modified IgG Heavy-Chain Capture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The heterogeneity of antibody molecules, particularly in recombinant monoclonal antibodies, leads to challenges in achieving consistent manufacturing and quality control during therapeutic monoclonal antibody production, with modifications such as C-terminal lysine and glycine cleavage affecting antibody function and specificity.
Innovation Solution
Development of antibodies that specifically bind to modified IgG heavy chain constant regions lacking glycine at position 446 and lysine at position 447, with an unamidated amino acid at position 445, allowing for selective recognition and capture of these modified regions while avoiding binding to other forms, thereby enhancing manufacturing consistency and quality control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If standard recombinant monoclonal antibody production is used, then therapeutic antibody supply is maintained, but C-terminal heterogeneity (delta-K, delta-GK-amide, wild-type variants) causes manufacturing inconsistency and quality control difficulties
Solution Approach 1:
The patent extracts and removes the problematic C-terminal residues (glycine at position 446 and lysine at position 447) from the antibody heavy chain constant region. By designing antibodies with a deleted GK motif at the C-terminus, the invention eliminates the source of heterogeneity caused by endogenous carboxypeptidase cleavage and PAM-mediated amidation, thereby achieving manufacturing consistency and molecular homogeneity without affecting therapeutic function
Solution Approach 2:
The patent changes the chemical structure parameter of the antibody C-terminus by genetically deleting specific amino acid residues (GK deletion). This structural modification prevents post-translational modifications (cleavage and amidation) that cause heterogeneity, transforming the antibody from a prone-to-heterogeneity structure to a stable, homogeneous structure suitable for consistent manufacturing
2Measurement precision
If antibodies against engineered Fc regions are developed, then specific detection and capture capability is improved, but antibody complexity increases
Solution Approach 1:
Instead of developing complex detection methods to identify heterogeneous antibody forms, the patent inverts the approach by engineering the antibody itself to have a unique, simplified C-terminal structure (delta-GK deletion). This inverted strategy allows standard detection methods to easily distinguish the engineered antibody from wild-type forms, achieving high detection specificity without increasing system complexity
Data Source
AI summary
An objective of the invention is to provide an antibody, a composition for use in detecting or capturing a polypeptide in a sample, and a method for detecting or capturing a polypeptide in sample. The disclosure provides an antibody, a composition for use in detecting or capturing a polypeptide in a sample, and a method for detecting or capturing a polypeptide in sample.